Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  therapeutic allogeneic lymphocytes
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 93 for your search:
Start Over
Safety and Effectiveness of Granulocyte Transfusions in Resolving Infection in People With Neutropenia (The RING Study)
Phase: Phase III
Type: Supportive care
Status: Completed
Age: Not specified
Sponsor: Other
Protocol IDs: 557, U01HL072268, HL072268, HL072291, HL072196, HL072248, HL072191, HL072305, HL072028, HL072072, HL072355, HL072283, HL072346, HL072331, HL072290, NCT00627393
Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 75 and under
Sponsor: NCI, Other
Protocol IDs: 1655.00, NCI-2009-01471, P01CA018029, FHCRC-1655.00, 5430, NCT00052520
Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: Any age
Sponsor: NCI, Other
Protocol IDs: 1803.00, NCI-2010-00163, P30CA015704, P01CA078902, FHCRC-1803.00, 5606, NCT00068718
Donor Natural Killer Cell Therapy and Aldesleukin in Treating Patients With High Risk Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 to 70
Sponsor: Other
Protocol IDs: 2004LS042, UMN-MT2003-23, UMN-IRB-0405M60481, UMN-2004LS042, NCT00303667
Prophylactic Transfer of Leukemia-reactive T Cells After Allogeneic Transplantation
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 to 60
Sponsor: Other
Protocol IDs: EK126092000, NCT00460629
Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 12 to 60
Sponsor: Other
Protocol IDs: CIK#2/2007, NMRC/1097/2006, NCT00460694
Fludarabine and PK-Directed Busulfan With or Without ATG Followed By Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Diseases
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 to 55
Sponsor: NCI, Other
Protocol IDs: LCCC 0510, P30CA016086, CDR0000550145, UNC-LCCC-0510, NCT00448357
A Phase I/II Study of Mis-Matched Immune Cells (AlloStim) in Patients With Advanced Hematological Malignancy
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ITL-001-HMC, NCT00558675
Most Closely HLA Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes (CTL)
Phase: Phase II, Phase I
Type: Supportive care
Status: Completed
Age: Not specified
Sponsor: Other
Protocol IDs: 22994-CHALLAH, CHALLAH, U54HL081007, NCT00711035
Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 15 to 75
Sponsor: Other
Protocol IDs: CDR0000632275, AMC-UUCM-2008-0383, 2008-0383, NCT00823524
High-dose Chemotherapy With Transplantation of Gene-modified Haematopoietic Stem Cells for HIV-positive Patients With Malignant Diseases Indicating an HSCT
Phase: Phase II, Phase I
Type: Treatment
Status: Temporarily closed
Age: 18 to 65
Sponsor: Other
Protocol IDs: ARL-GT 2005, NCT00858793
Chemotherapy Followed by Donor White Blood Cells Plus Interleukin-2 in Treating Patients With Acute Myeloid or Lymphocytic Leukemia
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: Not specified
Sponsor: NCI, Other
Protocol IDs: 1380.00, FHCRC-1380.00, NCI-H00-0057, CDR0000067777, NCT00005802
Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Stage IV Kidney Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: Under 75
Sponsor: NCI, Other
Protocol IDs: 1495.00, NCI-2012-00581, P30CA015704, FHCRC-1495.00, NCI-G00-1790, NCT00005851
Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: Under 75
Sponsor: NCI, Other
Protocol IDs: 1533.00, NCI-2013-01634, P01CA078902, P30CA015704, FHCRC-1533.00, NCI-H00-0062, NCT00006251
Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 1 to 74
Sponsor: NCI
Protocol IDs: 080051, 08-C-0051, NCT00923910
Combination Chemotherapy and Total-Body Irradiation Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Acute Lymphoblastic Leukemia
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 75 and under
Sponsor: NCI, Other
Protocol IDs: 1586.00, FHCRC-1586.00, NCI-H01-0080, CDR0000069042, NCT00027547
Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: Any age
Sponsor: NCI, Other
Protocol IDs: 1641.00, NCI-2012-00591, P30CA015704, P01CA018029, FHCRC-1641.00, NCI-H01-0081, NCT00027820
Reduced-Intensity Conditioning Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 to 70
Sponsor: NCI, Other
Protocol IDs: 1743.00, NCI-2011-00386, P30CA015704, FHCRC-1743.00, 5476, NCT00054353
Donor White Blood Cell Infusions and Interleukin-2 in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed Advanced Lymphoid Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 to 69
Sponsor: Other
Protocol IDs: 1838.00, FHCRC-1838.00, CDR0000430694, NCT00248430
Biological Therapy in Treating Patients With Multiple Myeloma That Has Recurred Following Bone Marrow Transplantation
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000065938, ECOG-E1A97, E1A97, NCT00003153
Phase II Study of Nonmyeloblative Allogeneic Peripheral Blood Stem Cell Transplantation and Donor Lymphocyte Infusions in Patients With Refractory Metastatic Solid Tumors
Phase: Phase II
Type: Treatment
Status: Closed
Age: 10 to 80
Sponsor: NHLBI
Protocol IDs: NHLBI-99-H-0064, NCT00003839
Start Over